Evaxion A/S

Evaxion A/S

Biotechnology • Healthcare • Horsholm, Denmark • EVAX (NCM)

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers, including non-small cell lung cancer. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, a viral vaccine product candidate for targeting Cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.

45 31 31 97 53 Dr. Neergaards Vej, Denmark

Stock Performance (90 Days)

Data through Dec 29, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Lake Street Raises Evaxion (EVAX) PT to $11 Following Positive Two-Year EVX-01 Melanoma Data - Yahoo Finance
Yahoo Finance • Oct 26
A potential gonorrhea vaccine loses one partner and seeks another - Stock Titan
Stock Titan • Dec 19
Lake Street Maintains Evaxion A (EVAX) Buy Recommendation - Nasdaq
Nasdaq • Oct 20
Evaxion Biotech stock soars after MSD licenses its vaccine candidate - Investing.com
Investing.com • Sep 25
Evaxion shares spike as AI-designed melanoma vaccine data hits market - Mugglehead Magazine
Mugglehead Magazine • Oct 15

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Evaxion A/S had layoffs?
No layoff events have been recorded for Evaxion A/S in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Evaxion A/S have?
Evaxion A/S has approximately 46 employees.
What industry is Evaxion A/S in?
Evaxion A/S operates in the Biotechnology industry, within the Healthcare sector.
Is Evaxion A/S a publicly traded company?
Yes, Evaxion A/S is publicly traded under the ticker symbol EVAX on the NCM. The company has a market capitalization of approximately $0.04 billion.
Where is Evaxion A/S headquartered?
Evaxion A/S is headquartered in Horsholm, Denmark at Dr. Neergaards Vej, Denmark.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.